Meiji Seika Pharma Co., Ltd.

This study tested two new antibiotic combinations (cefepime/nacubactam and aztreonam/nacubactam) against the best available treatments for serious, drug-resistant bacterial infections. It involved 126 hospitalized adults with infections like pneumonia, urinary tract infections, o…

This large, completed Phase 3 study tested whether two new combinations of antibiotics (cefepime/nacubactam and aztreonam/nacubactam) work as well as a standard antibiotic (imipenem/cilastatin) for treating serious urinary tract or kidney infections in adults. The main goal was t…